Literature DB >> 25428586

²³Na-MRI of recurrent glioblastoma multiforme after intraoperative radiotherapy: technical note.

Stefan Haneder1, Frank A Giordano, Simon Konstandin, Stefanie Brehmer, Karen A Buesing, Peter Schmiedek, Lothar R Schad, Frederik Wenz, Stefan O Schoenberg, Melissa M Ong.   

Abstract

INTRODUCTION: We report the first case of an intraoperative radiotherapy (IORT) in a patient with recurrent glioblastoma multiforme (GBM) who was followed up with a novel magnetic resonance imaging (MRI) method-(23)Na-MRI-in comparison to a standard contrast-enhanced (1)H-MRI and (18)F-FET-PET.
METHODS: A 56-year-old female patient with diagnosed GBM in July 2012 underwent tumor resection, radiochemotherapy, and three cycles of chemotherapy. After a relapse, 6 months after the initial diagnosis, an IORT was recommended which was performed in March 2013 using the INTRABEAM system (Carl Zeiss Meditec AG, Germany) with a 3-cm applicator and a surface dose of 20 Gy. Early post-operative contrast-enhanced and 1-month follow-up (1)H-MRI and a (18)F-FET-PET were performed. In addition, an IRB-approved (23)Na-MRI was performed on a 3.0-T MR scanner (MAGNETOM TimTrio, Siemens Healthcare, Germany).
RESULTS: After re-surgery and IORT in March 2013, only a faint contrast enhancement but considerable surrounding edema was visible at the medio-posterior resection margins. In April 2013, new and progressive contrast enhancement, edema, (23)Na content, and increased uptake in the (18)F-FET-PET were visible, indicating tumor recurrence. Increased sodium content within the area of contrast enhancement was found in the (23)Na-MRI, but also exceeding this area, very similar to the increased uptake depicted in the (18)F-FET-PET. The clearly delineable zone of edema in both examinations exhibits a lower (23)Na content compared to areas with suspected proliferating tumor tissue.
CONCLUSION: (23)Na-MRI provided similar information in the suspicious area compared to (18)F-FET-PET, exceeding conventional (1)H-MRI. Still, (23)Na-MRI remains an investigational technique, which is worth to be further evaluated.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25428586     DOI: 10.1007/s00234-014-1468-2

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  27 in total

1.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

Authors:  Patrick Y Wen; David R Macdonald; David A Reardon; Timothy F Cloughesy; A Gregory Sorensen; Evanthia Galanis; John Degroot; Wolfgang Wick; Mark R Gilbert; Andrew B Lassman; Christina Tsien; Tom Mikkelsen; Eric T Wong; Marc C Chamberlain; Roger Stupp; Kathleen R Lamborn; Michael A Vogelbaum; Martin J van den Bent; Susan M Chang
Journal:  J Clin Oncol       Date:  2010-03-15       Impact factor: 44.544

2.  Scale to predict survival after surgery for recurrent glioblastoma multiforme.

Authors:  John K Park; Tiffany Hodges; Leopold Arko; Michael Shen; Donna Dello Iacono; Adrian McNabb; Nancy Olsen Bailey; Teri Nguyen Kreisl; Fabio M Iwamoto; Joohee Sul; Sungyoung Auh; Grace E Park; Howard A Fine; Peter McL Black
Journal:  J Clin Oncol       Date:  2010-07-19       Impact factor: 44.544

Review 3.  Sodium MR imaging of acute and subacute stroke for assessment of tissue viability.

Authors:  Keith R Thulborn; Denise Davis; James Snyder; Howard Yonas; Amin Kassam
Journal:  Neuroimaging Clin N Am       Date:  2005-08       Impact factor: 2.264

4.  Sodium MRI using a density-adapted 3D radial acquisition technique.

Authors:  Armin M Nagel; Frederik B Laun; Marc-André Weber; Christian Matthies; Wolfhard Semmler; Lothar R Schad
Journal:  Magn Reson Med       Date:  2009-12       Impact factor: 4.668

5.  Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma.

Authors:  Florian Stockhammer; Martin Misch; Arend Koch; Marcus Czabanka; Michail Plotkin; Cristiane Blechschmidt; Jochen Tuettenberg; Peter Vajkoczy
Journal:  J Neurooncol       Date:  2010-05-06       Impact factor: 4.130

6.  Proton and sodium MRI assessment of emerging tumor chemotherapeutic resistance.

Authors:  Victor D Schepkin; Kuei C Lee; Kyle Kuszpit; Mukilan Muthuswami; Timothy D Johnson; Thomas L Chenevert; Alnawaz Rehemtulla; Brian D Ross
Journal:  NMR Biomed       Date:  2006-12       Impact factor: 4.044

7.  Sodium and proton diffusion MRI as biomarkers for early therapeutic response in subcutaneous tumors.

Authors:  Victor D Schepkin; Thomas L Chenevert; Kyle Kuszpit; Kuei C Lee; Charles R Meyer; Timothy D Johnson; Alnawaz Rehemtulla; Brian D Ross
Journal:  Magn Reson Imaging       Date:  2006-01-26       Impact factor: 2.546

8.  Application of 23Na MRI to monitor chemotherapeutic response in RIF-1 tumors.

Authors:  Andriy M Babsky; Shahryar K Hekmatyar; Hong Zhang; James L Solomon; Navin Bansal
Journal:  Neoplasia       Date:  2005-07       Impact factor: 5.715

9.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.

Authors:  Teri N Kreisl; Lyndon Kim; Kraig Moore; Paul Duic; Cheryl Royce; Irene Stroud; Nancy Garren; Megan Mackey; John A Butman; Kevin Camphausen; John Park; Paul S Albert; Howard A Fine
Journal:  J Clin Oncol       Date:  2008-12-29       Impact factor: 44.544

Review 10.  The role of imaging in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.

Authors:  Timothy Charles Ryken; Nafi Aygun; Johnathan Morris; Marin Schweizer; Rajeshwari Nair; Cassandra Spracklen; Steven N Kalkanis; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2014-04-09       Impact factor: 4.130

View more
  5 in total

Review 1.  Quantitative sodium MR imaging: A review of its evolving role in medicine.

Authors:  Keith R Thulborn
Journal:  Neuroimage       Date:  2016-11-24       Impact factor: 6.556

2.  Sodium MRI at 7T for Early Response Evaluation of Intracranial Tumors following Stereotactic Radiotherapy Using the CyberKnife.

Authors:  L Huang; J Bai; R Zong; J Zhou; Z Zuo; X Chai; Z Wang; J An; Y Zhuo; F Boada; X Yu; Z Ling; B Qu; L Pan; Z Zhang
Journal:  AJNR Am J Neuroradiol       Date:  2022-02       Impact factor: 3.825

3.  Assessment of Sodium MRI at 7 Tesla as Predictor of Therapy Response and Survival in Glioblastoma Patients.

Authors:  Daniel Paech; Sebastian Regnery; Tanja Platt; Nicolas G R Behl; Nina Weckesser; Paul Windisch; Katerina Deike-Hofmann; Wolfgang Wick; Martin Bendszus; Stefan Rieken; Laila König; Mark E Ladd; Heinz-Peter Schlemmer; Jürgen Debus; Sebastian Adeberg
Journal:  Front Neurosci       Date:  2021-12-01       Impact factor: 4.677

Review 4.  High-Grade Glioma Treatment Response Monitoring Biomarkers: A Position Statement on the Evidence Supporting the Use of Advanced MRI Techniques in the Clinic, and the Latest Bench-to-Bedside Developments. Part 2: Spectroscopy, Chemical Exchange Saturation, Multiparametric Imaging, and Radiomics.

Authors:  Thomas C Booth; Evita C Wiegers; Esther A H Warnert; Kathleen M Schmainda; Frank Riemer; Ruben E Nechifor; Vera C Keil; Gilbert Hangel; Patrícia Figueiredo; Maria Del Mar Álvarez-Torres; Otto M Henriksen
Journal:  Front Oncol       Date:  2022-02-28       Impact factor: 5.738

5.  Ultra-high-field sodium MRI as biomarker for tumor extent, grade and IDH mutation status in glioma patients.

Authors:  Sebastian Regnery; Nicolas G R Behl; Tanja Platt; Nina Weinfurtner; Paul Windisch; Katerina Deike-Hofmann; Felix Sahm; Martin Bendszus; Jürgen Debus; Mark E Ladd; Heinz-Peter Schlemmer; Stefan Rieken; Sebastian Adeberg; Daniel Paech
Journal:  Neuroimage Clin       Date:  2020-09-12       Impact factor: 4.881

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.